The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery.
As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.
Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.
This study is being done to compare two standard treatment regimens for acute myeloid leukemia (AML). The first treatment regimen is called DA-90, which involves standard of care drugs daunorubicin (DNR) and Ara-C, is a standard of care upfront treatment regimen for untreated AML.
- Subjects must have a diagnosis of previously untreated acute myeloid leukemia (either AML de novo, AML secondary to myelodysplastic syndromes, or AML secondary towards used therapies or agents which can induce leukemia)
- Subjects must be at least 18 years old and no greater than 60 years old.
- Subjects must have a clinical condition allowing induction treatment to be performed.
- Subjects must have normal liver and kidney function.
*Detailed eligibility criteria will be reviewed when you contact the study team.
Our randomized trial will compare the safety and efficacy of MRI-guided transperineal (TP) versus transrectal ultrasound guided (TRUS) biopsies performed in the outpatient setting. Currently, both methods are standard of care procedures.
- Open to men 18 years or older with suspicion for prostate cancer based upon an elevated PSA or abnormal digital rectal examination (DRE)
- Men with active urinary tract infection, metastatic prostate cancer, history of colorectal surgery limiting insertion of transrectal probe, evidence of acute or chronic prostatitis, or concern for perineal cellulitis or fistula will be excluded.
Certain types of antibodies in the blood may injure a transplanted kidney. Antibodies are types of proteins in the blood that help fight things that are not a part of your own body, like infections.
- Have human leukocyte antigen (HLA) donor-specific antibody (DSA) identified at the time of diagnosis of AMR.
- Have a first qualifying episode of AMR in the participant's current renal allograft between 72 hours (h) and 12 months after transplant.
- Receive first dose of investigational product after 7 days after the kidney transplant procedure and within 7 days after the qualifying renal allograft biopsy procedure that was positive for AMR.
- Have received pediatric en bloc kidney transplant.
- Have primary Focal Segmental Glomerulosclerosis.
- Have prior or concurrent non-renal solid organ transplant or hematopoietic stem cell transplant (HSCT).
- Have a known neoplastic lesion in the transplanted allograft
- Have any ongoing infection
- Have ongoing treatment for hepatitis C virus (HCV) infection.
- Have had a recent myocardial infarction (MI) within the past 6 months and/or at the time of screening.
- Have a history of: abnormal bleeding, clotting events or disorders.
- Have a history of allergic reaction to CINRYZE or other blood products.
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).
- Men age 18 an older
- Documented progressive metastatic castration-resistant prostate cancer
- Adequate organ function
- Detailed eligibility reviewed when you contact the study team
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the change in body weight from baseline and to assess the safety and tolerability of JNJ-64565111 in non-diabetic severely obese participants.
- Men and women age 18-70
- BMI ≥ 35 to ≤ 5 0 kg/m2 at the screening visit
- Stable weight (that is, change of < 5% within 12 weeks before screening based on medical history)
- No personal history of the following: Type 1 diabetes mellitus, T2DM, MI, unstable angina, revascularization procedure cardiac pacemaker or other electric implantable device, significant liver disease, pancreatitis, bariatric surgical procedure or a known clinically significant gastric emptying abnormality
- Detailed eligibility reviewed when you contact the study team.
This clinical trial is for men and women with glioblastoma that has recurred or progressed. There is currently a need for more effective treatment methods for this disease.
- Open to men and women above the age of 18
- Diagnosed with glioblastoma (GBM) at first recurrence or progression following primary therapy consisting of surgery (biopsy or resection) and chemoradiation
- Detailed eligibility will be reviewed when you contact the study team
Complicated intra-abdominal infections, also referred to as cIAIs, are serious bacterial infections of the abdomen such as:
• Burst appendix: when an infected appendix, a pouch connected to the large intestine, bursts
You might be able to take part in the Caspian-Andi study if you:
• Are between 3 months and up to (but not including) 18 years old
• Have a complicated infection of the abdomen (cIAI)
• Need surgery and antibiotic therapy (via a tube in the vein or ‘IV’) to help treat your infection
Other criteria will be discussed with the study team.
This clinical trial is for men and women with meningioma. Currently available treatments are not effective in treating patients with this disease. Therefore, there is a need to find treatments that work for patients with meningoioma.
- Men and women age 18 and older
- Diagnosis of meningioma
- Open to untreated and previously treated patients
- Detailed eligibility reviewed when you contact the study team.
The purpose of this study is to examine brain cancer patients’ surgically removed tumors for certain molecular changes that may make them eligible to participate in the related treatment study.
• Open to men and women age 18 and older
• Patients have not had a local MGMT testing
• Newly diagnosed Grade IV intracranial gliobastoma or gliosarcoma
• Patients must have completed standard radiotherapy and TMZ therapy
• No other therapy has been done (Neoadjuvant or adjuvant) which includes chemotherapy, biologics, immunotherapy, and radiation therapy.
• Detailed eligibility reviewed when you contact the study team.